These are the same general criteria used for brand-name semaglutide
Cardiovasc Diabetol 20:32 Hundertmark MJ, Agbaje OF, Coleman R, George JT, Grempler R, Holman RR, Lamlum H, Lee J, Milton JE, Niessen HG, Rider O, Rodgers CT, Valkovi L, Wicks E, Mahmod M, Neubauer S (2021) Design and rationale of the EMPA-VISION trial: investigating the metabolic effects of empagliflozin in patients with heart failure
ROR = 9.59, 95% CI 9.0910.12), all of which are consistent with established safety profiles documented in the prescribing information
As a locally operated clinic in Essex County, we bring trusted protocols and the latest advancements in vitamin infusions, NAD+ therapy, and medical-grade hydration to the Andover community
You should not submit a Yellow Card report for events occurring within a clinical trial unless specifically instructed to do so by the study team